



Transparency notification

Shareholding on 29 February 2012 (according to Article 6 and 14 of the law of 2 May 2007 on the disclosure of large shareholdings).

Brussels (Belgium), 1 March 2012 – 18.30 PM CET – regulated information – UCB SA/NV received on 1 March 2012 various transparency notifications.

On 28 February 2012, the concerts between Financière de Tubize SA and (i) Degroof Corporate Finance SA, Imofig SA and Levimmo SA, (ii) Compar Finance SA, (iii) Pharmahold SA and Cosylva SA, respectively, ended.

The concert between Financière de Tubize SA and Schwarz Vermögensverwaltung GmbH & Co KG remains in place (jointly 40.76% of the voting rights).

On 29 February 2012, Pharmahold SA, Cosylva SA and Compar Finance SA entered into a new concert agreement relating to their shares in UCB SA/NV (jointly 4.40% of the voting rights).

An updated chart with the total number of securities and the percentage of voting rights attached thereto is included in the corporate governance charter of UCB SA/NV, which is published on UCB SA/NV's website. UCB SA/NV also published the transparency notifications on its website.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608

For further information

Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@uctb.com

About UCB

UCB, Brussels, Belgium (www.uctb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated



with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.